证券代码：002160 证券简称：常铝股份 公告编号：2025-047 江苏常铝铝业集团股份有限公司 关于间接股东国有股权行政划转 及披露详式权益变动报告书的提示性公告 信息披露义务人济南工业投资控股有限公司（以下简称"济南工控"）应 保证向本公司提供的信息内容真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏；本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 重要内容提示： 1、本次间接控股股东济南产业发展投资集团有限公司（以下简称"济南产 发"）及间接股东济钢集团有限公司（以下简称"济钢集团"）上层股权结构调 整不会导致公司直接控股股东、最终实际控制人发生变化，公司的直接控股股东 仍为齐鲁财金投资集团有限公司（以下简称"齐鲁财金"），最终实际控制人仍 为济南市人民政府国有资产监督管理委员会（以下简称"济南市国资委"）；本 次间接控股股东济南产发上层股权结构调整完成后，济南工控将通过济南产发间 接控制公司直接控股股东齐鲁财金。 2、本次权益变动不触及要约收购。 注：根据济南市国资委出具的《关于济南产业发展投资集团有限公司股 权无偿划转的通知》（济国资产权[2025]12号）、《股东 ...

证券代码：002160 证券简称：常铝股份 公告编号：2025-046 江苏常铝铝业集团股份有限公司 关于对子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 江苏常铝铝业集团股份有限公司（以下简称"公司"）于2025年03月14日召 开的第七届董事会第十九次（临时）会议、2025年03月31日召开的2025年第一次 临时股东大会审议并通过了《关于2025年度担保额度预计的议案》，同意公司2025 年度向各子公司提供总额不超过160,000万元担保额度，其中向上海朗脉洁净技 术股份有限公司（以下简称"上海朗脉"）提供担保的总额度不超过80,000万元， 期限自股东大会审议通过之日起至下年度审议对外担保额度预计的股东大会审 议通过之日止，任一时点的担保余额不得超过股东大会审议通过的担保额度。具 体 内 容详 见于 2025年 03 月 15 日在 指定媒 体 《证 券时 报》及 巨 潮资 讯 网 （www.cninfo.com.cn）刊登的《关于2025年度提供担保额度预计的公告》（公 告编号：2025-007）。 二、担 ...

Group 1 - The company approved a guarantee limit of up to 1.6 billion yuan for the year 2025, with a specific limit of 500 million yuan for Baotou Chang Aluminum [1] - The financing lease business is authorized for a total amount not exceeding 500 million yuan, with the ability to use the amount cyclically within the authorized period [2] - Baotou Chang Aluminum signed a financing lease contract with Jiangsu Financial Leasing Co., Ltd. for a principal amount of 100 million yuan, with a lease term of 24 months [2][3] Group 2 - The company holds 100% equity in Baotou Chang Aluminum, which has total assets of approximately 1.88 billion yuan and net assets of approximately 694.79 million yuan as of March 31, 2025 [7] - Baotou Chang Aluminum reported a total revenue of approximately 899.16 million yuan for the first quarter of 2025, with a net loss of approximately 14.82 million yuan [7] - The company has no overdue guarantees and has provided guarantees only within the scope of consolidated financial statements [8]

江苏常铝铝业集团股份有限公司 证券代码：002160 证券简称：常铝股份 公告编号：2025-045 关于子公司开展融资租赁业务及公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保及融资租赁情况概述 （一）担保情况概述 江苏常铝铝业集团股份有限公司（以下简称"公司"）于 2025 年 03 月 14 日召开的第七届董事会第十九次（临时）会议、2025 年 03 月 31 日召开的 2025 年第一次临时股东大会审议并通过了《关于 2025 年度担保额度预计的议案》， 同意公司 2025 年度向各子公司提供总额不超过 160,000 万元担保额度，其中向 包头常铝北方铝业有限责任公司（以下简称"包头常铝"）提供担保的总额度不 超过 50,000 万元，期限自股东大会审议通过之日起至下年度审议对外担保额度 预计的股东大会审议通过之日止，任一时点的担保余额不得超过股东大会审议通 过的担保额度。具体内容详见公司于 2025 年 03 月 15 日在指定媒体《证券时报》 及巨潮资讯网（www.cninfo.com.cn）刊登的《关于 ...

Core Viewpoint - Chang Aluminum Co., Ltd. has signed significant contracts in the medical cleanroom sector, indicating a positive outlook for its healthcare business segment [1][2]. Group 1: Contract Details - The company’s subsidiary, Shanghai Langmai, signed a supply contract with Kanglwei (Kunming) Biotechnology Co., Ltd. worth 165 million yuan, which is expected to positively impact the healthcare business [1][2]. - In March, Shanghai Langmai also secured a contract with Chongqing Wangye Biopharmaceutical Co., Ltd. for 145 million yuan, bringing the total contract value for the year to 310 million yuan [3]. Group 2: Financial Performance - The healthcare cleanroom business has shown steady growth, with revenues increasing from 584 million yuan in 2022 to 798 million yuan in 2023, marking a growth rate of 36.64%, and projected to reach 898 million yuan in 2024, a 12.53% increase [3]. - The aluminum foil manufacturing business generated revenues of 6.2 billion yuan in 2022, 6.08 billion yuan in 2023, and is expected to reach 6.95 billion yuan in 2024, accounting for approximately 88% of total revenue [4]. Group 3: Research and Development Investment - The company has invested nearly 1 billion yuan in research and development from 2022 to 2024, with a focus on enhancing product competitiveness [1][6]. - In 2024, the company filed 114 patent applications, including 35 invention patents, and holds a total of 405 authorized patents [6].

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002160 证券简称：常铝股份 公告编号：2025-044 江苏常铝铝业集团股份有限公司 关于下属子公司签订日常经营合同的公告 合同在未来履行过程中可能存在违约风险；如遇政策、市场环境重大变化等 不可抗力因素的影响，可能会导致合同存在无法全部履行或终止履行的风险。 一、合同签署概况 近日，江苏常铝铝业集团股份有限公司（以下简称"公司"）全资子公司上 海朗脉洁净技术股份有限公司（以下简称"上海朗脉"）与康乐卫士（昆明）生 物技术有限公司（以下简称"康乐卫士"）签订《重组疫苗临床及产业化基地厂 房定制化建设项目（一期）5#楼3层HPV九价原液车间项目洁净装修、机电安装及 设备供货总承包合同》，由上海朗脉负责康乐卫士重组疫苗临床及产业化基地厂 房定制化建设项目（一期）5#楼3层HPV九价原液车间项目洁净装修、机电安装及 设备供货总承包施工及设备供货。 根据有关规则及《公司章程》等的规定，该合同的签订无需经公司董事会以 及股东大会审议。本次交易不构成关联交易和《上市公司重大资产重组管理办法》 所规 ...

Group 1 - The core point of the article is that Chang Aluminum Co., Ltd. announced a contract worth RMB 165 million with Kang Le Wei Shi (Kunming) Biotechnology Co., Ltd. for the construction of a cleanroom facility for HPV vaccine production [1] - The contract represents 18.11% of Shanghai Langmai's audited main business revenue for the year 2024, indicating a significant contribution to the company's financials [1] - The signing of this contract is expected to have a positive impact on the company's medical clean health business segment [1]

证券代码：002160 证券简称：常铝股份 公告编号：2025-043 江苏常铝铝业集团股份有限公司 关于全资子公司为孙公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、担保情况概述 二、担保进展情况 （一）上海朗脉下属控股子公司常州朗脉洁净技术有限公司（以下简称"常州 朗脉"）因其经营需要，向中国民生银行股份有限公司上海分行（以下简称"民生 银行"）申请人民币1000万元综合授信额度，期限为壹年。 （二）为保证上述融资事项的顺利进行，上海朗脉拟与民生银行签订担保合同， 为常州朗脉向民生银行申请的银行融资事项提供连带责任担保，担保额度为1000万 元。 近日，上海朗脉已就上述担保事项履行了其内部审议程序。 根据《深圳证券交易所股票上市规则》等的相关规定，上述担保事项无需再次 提交公司董事会或股东大会审议。 三、被担保人基本情况 江苏常铝铝业集团股份有限公司（以下简称"公司"）于2025年03月14日召开 的第七届董事会第十九次（临时）会议、2025年03月31日召开的2025年第一次临时 股东大会审议并通过了《关于2025年度担保额度预计 ...